Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy
Volume: 3, Issue: 3, Pages: 339 - 347
Published: May 10, 2017
Abstract
Introduction Multiple intravenous doses of ponezumab, an anti‐amyloid antibody, were evaluated in subjects with mild‐to‐moderate Alzheimer's disease (AD). Methods In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo. Subjects received 10 infusions over 18 months and were followed...
Paper Details
Title
Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy
Published Date
May 10, 2017
Volume
3
Issue
3
Pages
339 - 347
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History